APO Research
Talk to an analyst

APO RESEARCH · REPORT

Liposome Finished Pharmaceuticals

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Liposome Finished Pharmaceuticals Market Outlook and Growth Opportunities 2026

21 December 2025200 pages

Choose your research edition.

Industry ResearchLiposome Finished Pharmaceuticals Industry Research Report 2026141 pages · $2,950 USDIndustry Growth & TrendsGlobal Liposome Finished Pharmaceuticals Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Liposome Finished Pharmaceuticals Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Liposome Finished Pharmaceuticals Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Liposome Finished Pharmaceuticals Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Liposome Finished Pharmaceuticals market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Liposome Finished Pharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Liposome Finished Pharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Liposome Finished Pharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Liposome Finished Pharmaceuticals market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Liposome Finished Pharmaceuticals market include Takeda, Teva, Sun Pharmaceutical, Johnson & Johnson, Chiesi Farmaceutici, Gilead Sciences, Zydus Cadila, TTY Biopharma and Sayre Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Liposome Finished Pharmaceuticals market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Liposome Finished Pharmaceuticals and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Liposome Finished Pharmaceuticals revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Liposome Finished Pharmaceuticals market.

Liposome Finished Pharmaceuticals Segment by Company

Takeda

Teva

Sun Pharmaceutical

Johnson & Johnson

Chiesi Farmaceutici

Gilead Sciences

Zydus Cadila

TTY Biopharma

Sayre Therapeutics

Pacira

Luye Pharma

Leadiant Biosciences

Kinyond

Jazz

Ipsen

Fudan-Zhangjiang

CSPC

Bausch Health

Alnylam

Acrotech Biopharma

Liposome Finished Pharmaceuticals Segment by Type

Liposomes Drugs

Lipid Nanoparticle Drugs

Liposome Finished Pharmaceuticals Segment by Application

Hospital

Retail Pharmacy

Other

Liposome Finished Pharmaceuticals Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Liposome Finished Pharmaceuticals status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Liposome Finished Pharmaceuticals key companies, revenue, market share, and recent developments.

3. To split the Liposome Finished Pharmaceuticals breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Liposome Finished Pharmaceuticals market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Liposome Finished Pharmaceuticals significant trends, drivers, influence factors in global and regions.

6. To analyze Liposome Finished Pharmaceuticals competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liposome Finished Pharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Liposome Finished Pharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liposome Finished Pharmaceuticals.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Liposome Finished Pharmaceuticals industry.

Chapter 3: Detailed analysis of Liposome Finished Pharmaceuticals company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Liposome Finished Pharmaceuticals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Liposome Finished Pharmaceuticals in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Liposome Finished Pharmaceuticals Industry Trends Table 2. Liposome Finished Pharmaceuticals Industry Drivers Table 3. Liposome Finished Pharmaceuticals Industry Opportunities and Challenges Table 4. Liposome Finished Pharmaceuticals Industry Restraints Table 5. Global Liposome Finished Pharmaceuticals Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Liposome Finished Pharmaceuticals Revenue Share by Company (2021-2026) Table 7. Global Liposome Finished Pharmaceuticals Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Liposome Finished Pharmaceuticals Key Company Manufacturing Base & Headquarters Table 9. Global Liposome Finished Pharmaceuticals Company, Product Type & Application Table 10. Global Liposome Finished Pharmaceuticals Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Liposome Finished Pharmaceuticals by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Liposomes Drugs Table 15. Significant Companies of Lipid Nanoparticle Drugs Table 16. Global Liposome Finished Pharmaceuticals Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Liposome Finished Pharmaceuticals Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Liposome Finished Pharmaceuticals Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Liposome Finished Pharmaceuticals Sales Value Share by Type (2021-2026) Table 20. Global Liposome Finished Pharmaceuticals Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Retail Pharmacy Table 23. Significant Companies of Other Table 24. Global Liposome Finished Pharmaceuticals Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Liposome Finished Pharmaceuticals Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Liposome Finished Pharmaceuticals Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Liposome Finished Pharmaceuticals Sales Value Share by Application (2021-2026) Table 28. Global Liposome Finished Pharmaceuticals Sales Value Share by Application (2027-2032) Table 29. Global Liposome Finished Pharmaceuticals Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Liposome Finished Pharmaceuticals Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Liposome Finished Pharmaceuticals Sales Value Share by Region (2021-2026) Table 32. Global Liposome Finished Pharmaceuticals Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Liposome Finished Pharmaceuticals Sales Value Share by Region (2027-2032) Table 34. Global Liposome Finished Pharmaceuticals Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Liposome Finished Pharmaceuticals Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Liposome Finished Pharmaceuticals Sales Value Market Share by Country (2021-2026) Table 37. Global Liposome Finished Pharmaceuticals Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Liposome Finished Pharmaceuticals Sales Value Market Share by Country (2027-2032) Table 39. Takeda Company Information Table 40. Takeda Business Overview Table 41. Takeda Liposome Finished Pharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Takeda Liposome Finished Pharmaceuticals Product Portfolio Table 43. Takeda Recent Development Table 44. Teva Company Information Table 45. Teva Business Overview Table 46. Teva Liposome Finished Pharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Teva Liposome Finished Pharmaceuticals Product Portfolio Table 48. Teva Recent Development Table 49. Sun Pharmaceutical Company Information Table 50. Sun Pharmaceutical Business Overview Table 51. Sun Pharmaceutical Liposome Finished Pharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Sun Pharmaceutical Liposome Finished Pharmaceuticals Product Portfolio Table 53. Sun Pharmaceutical Recent Development Table 54. Johnson & Johnson Company Information Table 55. Johnson & Johnson Business Overview Table 56. Johnson & Johnson Liposome Finished Pharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Johnson & Johnson Liposome Finished Pharmaceuticals Product Portfolio Table 58. Johnson & Johnson Recent Development Table 59. Chiesi Farmaceutici Company Information Table 60. Chiesi Farmaceutici Business Overview Table 61. Chiesi Farmaceutici Liposome Finished Pharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Chiesi Farmaceutici Liposome Finished Pharmaceuticals Product Portfolio Table 63. Chiesi Farmaceutici Recent Development Table 64. Gilead Sciences Company Information Table 65. Gilead Sciences Business Overview Table 66. Gilead Sciences Liposome Finished Pharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Gilead Sciences Liposome Finished Pharmaceuticals Product Portfolio Table 68. Gilead Sciences Recent Development Table 69. Zydus Cadila Company Information Table 70. Zydus Cadila Business Overview Table 71. Zydus Cadila Liposome Finished Pharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Zydus Cadila Liposome Finished Pharmaceuticals Product Portfolio Table 73. Zydus Cadila Recent Development Table 74. TTY Biopharma Company Information Table 75. TTY Biopharma Business Overview Table 76. TTY Biopharma Liposome Finished Pharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. TTY Biopharma Liposome Finished Pharmaceuticals Product Portfolio Table 78. TTY Biopharma Recent Development Table 79. Sayre Therapeutics Company Information Table 80. Sayre Therapeutics Business Overview Table 81. Sayre Therapeutics Liposome Finished Pharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Sayre Therapeutics Liposome Finished Pharmaceuticals Product Portfolio Table 83. Sayre Therapeutics Recent Development Table 84. Pacira Company Information Table 85. Pacira Business Overview Table 86. Pacira Liposome Finished Pharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Pacira Liposome Finished Pharmaceuticals Product Portfolio Table 88. Pacira Recent Development Table 89. Luye Pharma Company Information Table 90. Luye Pharma Business Overview Table 91. Luye Pharma Liposome Finished Pharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Luye Pharma Liposome Finished Pharmaceuticals Product Portfolio Table 93. Luye Pharma Recent Development Table 94. Leadiant Biosciences Company Information Table 95. Leadiant Biosciences Business Overview Table 96. Leadiant Biosciences Liposome Finished Pharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Leadiant Biosciences Liposome Finished Pharmaceuticals Product Portfolio Table 98. Leadiant Biosciences Recent Development Table 99. Kinyond Company Information Table 100. Kinyond Business Overview Table 101. Kinyond Liposome Finished Pharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Kinyond Liposome Finished Pharmaceuticals Product Portfolio Table 103. Kinyond Recent Development Table 104. Jazz Company Information Table 105. Jazz Business Overview Table 106. Jazz Liposome Finished Pharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Jazz Liposome Finished Pharmaceuticals Product Portfolio Table 108. Jazz Recent Development Table 109. Ipsen Company Information Table 110. Ipsen Business Overview Table 111. Ipsen Liposome Finished Pharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Ipsen Liposome Finished Pharmaceuticals Product Portfolio Table 113. Ipsen Recent Development Table 114. Fudan-Zhangjiang Company Information Table 115. Fudan-Zhangjiang Business Overview Table 116. Fudan-Zhangjiang Liposome Finished Pharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Fudan-Zhangjiang Liposome Finished Pharmaceuticals Product Portfolio Table 118. Fudan-Zhangjiang Recent Development Table 119. CSPC Company Information Table 120. CSPC Business Overview Table 121. CSPC Liposome Finished Pharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. CSPC Liposome Finished Pharmaceuticals Product Portfolio Table 123. CSPC Recent Development Table 124. Bausch Health Company Information Table 125. Bausch Health Business Overview Table 126. Bausch Health Liposome Finished Pharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. Bausch Health Liposome Finished Pharmaceuticals Product Portfolio Table 128. Bausch Health Recent Development Table 129. Alnylam Company Information Table 130. Alnylam Business Overview Table 131. Alnylam Liposome Finished Pharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 132. Alnylam Liposome Finished Pharmaceuticals Product Portfolio Table 133. Alnylam Recent Development Table 134. Acrotech Biopharma Company Information Table 135. Acrotech Biopharma Business Overview Table 136. Acrotech Biopharma Liposome Finished Pharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 137. Acrotech Biopharma Liposome Finished Pharmaceuticals Product Portfolio Table 138. Acrotech Biopharma Recent Development Table 139. Research Programs/Design for This Report Table 140. Authors List of This Report Table 141. Secondary Sources Table 142. Primary Sources List of Figures Figure 1. Liposome Finished Pharmaceuticals Product Image Figure 2. Global Liposome Finished Pharmaceuticals Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Liposome Finished Pharmaceuticals Market Size (2021-2032) & (US$ Million) Figure 4. Global Liposome Finished Pharmaceuticals Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Liposomes Drugs Image Figure 8. Lipid Nanoparticle Drugs Image Figure 9. Global Liposome Finished Pharmaceuticals Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Liposome Finished Pharmaceuticals Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Liposome Finished Pharmaceuticals Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Retail Pharmacy Image Figure 14. Other Image Figure 15. Global Liposome Finished Pharmaceuticals Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Liposome Finished Pharmaceuticals Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Liposome Finished Pharmaceuticals Sales Value Share by Application (2021-2032) Figure 18. Global Liposome Finished Pharmaceuticals Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Liposome Finished Pharmaceuticals Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Liposome Finished Pharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 21. North America Liposome Finished Pharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Liposome Finished Pharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Liposome Finished Pharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Liposome Finished Pharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Liposome Finished Pharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Liposome Finished Pharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 27. South America Liposome Finished Pharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Liposome Finished Pharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Liposome Finished Pharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Liposomes Drugs
  • Lipid Nanoparticle Drugs
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Takeda
  • Teva
  • Sun Pharmaceutical
  • Johnson & Johnson
  • Chiesi Farmaceutici
  • Gilead Sciences
  • Zydus Cadila
  • TTY Biopharma
  • Sayre Therapeutics
  • Pacira
  • Luye Pharma
  • Leadiant Biosciences
  • Kinyond
  • Jazz
  • Ipsen
  • Fudan-Zhangjiang
  • CSPC
  • Bausch Health
  • Alnylam
  • Acrotech Biopharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Liposome Finished Pharmaceuticals Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Liposome Finished Pharmaceuticals Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Liposome Finished Pharmaceuticals Market Dynamics
  1. 2.1 Liposome Finished Pharmaceuticals Industry Trends
  2. 2.2 Liposome Finished Pharmaceuticals Industry Drivers
  3. 2.3 Liposome Finished Pharmaceuticals Industry Opportunities and Challenges
  4. 2.4 Liposome Finished Pharmaceuticals Industry Restraints
3 Liposome Finished Pharmaceuticals Market by Company
  1. 3.1 Global Liposome Finished Pharmaceuticals Company Revenue Ranking in 2025
  2. 3.2 Global Liposome Finished Pharmaceuticals Revenue by Company (2021-2026)
  3. 3.3 Global Liposome Finished Pharmaceuticals Company Ranking (2024-2026)
  4. 3.4 Global Liposome Finished Pharmaceuticals Company Manufacturing Base and Headquarters
  5. 3.5 Global Liposome Finished Pharmaceuticals Company Product Type and Application
  6. 3.6 Global Liposome Finished Pharmaceuticals Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Liposome Finished Pharmaceuticals Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Liposome Finished Pharmaceuticals Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Liposome Finished Pharmaceuticals Market by Type
  1. 4.1 Liposome Finished Pharmaceuticals Type Introduction
  2. 4.1.1 Liposomes Drugs
  3. 4.1.2 Lipid Nanoparticle Drugs
  4. 4.2 Global Liposome Finished Pharmaceuticals Sales Value by Type
  5. 4.2.1 Global Liposome Finished Pharmaceuticals Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Liposome Finished Pharmaceuticals Sales Value by Type (2021-2032)
  7. 4.2.3 Global Liposome Finished Pharmaceuticals Sales Value Share by Type (2021-2032)
5 Liposome Finished Pharmaceuticals Market by Application
  1. 5.1 Liposome Finished Pharmaceuticals Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Liposome Finished Pharmaceuticals Sales Value by Application
  6. 5.2.1 Global Liposome Finished Pharmaceuticals Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Liposome Finished Pharmaceuticals Sales Value by Application (2021-2032)
  8. 5.2.3 Global Liposome Finished Pharmaceuticals Sales Value Share by Application (2021-2032)
6 Liposome Finished Pharmaceuticals Regional Value Analysis
  1. 6.1 Global Liposome Finished Pharmaceuticals Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Liposome Finished Pharmaceuticals Sales Value by Region (2021-2032)
  3. 6.2.1 Global Liposome Finished Pharmaceuticals Sales Value by Region: 2021-2026
  4. 6.2.2 Global Liposome Finished Pharmaceuticals Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Liposome Finished Pharmaceuticals Sales Value (2021-2032)
  7. 6.3.2 North America Liposome Finished Pharmaceuticals Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Liposome Finished Pharmaceuticals Sales Value (2021-2032)
  10. 6.4.2 Europe Liposome Finished Pharmaceuticals Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Liposome Finished Pharmaceuticals Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Liposome Finished Pharmaceuticals Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Liposome Finished Pharmaceuticals Sales Value (2021-2032)
  16. 6.6.2 South America Liposome Finished Pharmaceuticals Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Liposome Finished Pharmaceuticals Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Liposome Finished Pharmaceuticals Sales Value Share by Country, 2025 VS 2032
7 Liposome Finished Pharmaceuticals Country-level Value Analysis
  1. 7.1 Global Liposome Finished Pharmaceuticals Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Liposome Finished Pharmaceuticals Sales Value by Country (2021-2032)
  3. 7.2.1 Global Liposome Finished Pharmaceuticals Sales Value by Country (2021-2026)
  4. 7.2.2 Global Liposome Finished Pharmaceuticals Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Liposome Finished Pharmaceuticals Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Liposome Finished Pharmaceuticals Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Liposome Finished Pharmaceuticals Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Liposome Finished Pharmaceuticals Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Liposome Finished Pharmaceuticals Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Liposome Finished Pharmaceuticals Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Liposome Finished Pharmaceuticals Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Sun Pharmaceutical
  14. 8.3.1 Sun Pharmaceutical Company Information
  15. 8.3.2 Sun Pharmaceutical Business Overview
  16. 8.3.3 Sun Pharmaceutical Liposome Finished Pharmaceuticals Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sun Pharmaceutical Liposome Finished Pharmaceuticals Product Portfolio
  18. 8.3.5 Sun Pharmaceutical Recent Developments
  19. 8.4 Johnson & Johnson
  20. 8.4.1 Johnson & Johnson Company Information
  21. 8.4.2 Johnson & Johnson Business Overview
  22. 8.4.3 Johnson & Johnson Liposome Finished Pharmaceuticals Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Johnson & Johnson Liposome Finished Pharmaceuticals Product Portfolio
  24. 8.4.5 Johnson & Johnson Recent Developments
  25. 8.5 Chiesi Farmaceutici
  26. 8.5.1 Chiesi Farmaceutici Company Information
  27. 8.5.2 Chiesi Farmaceutici Business Overview
  28. 8.5.3 Chiesi Farmaceutici Liposome Finished Pharmaceuticals Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Chiesi Farmaceutici Liposome Finished Pharmaceuticals Product Portfolio
  30. 8.5.5 Chiesi Farmaceutici Recent Developments
  31. 8.6 Gilead Sciences
  32. 8.6.1 Gilead Sciences Company Information
  33. 8.6.2 Gilead Sciences Business Overview
  34. 8.6.3 Gilead Sciences Liposome Finished Pharmaceuticals Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Gilead Sciences Liposome Finished Pharmaceuticals Product Portfolio
  36. 8.6.5 Gilead Sciences Recent Developments
  37. 8.7 Zydus Cadila
  38. 8.7.1 Zydus Cadila Company Information
  39. 8.7.2 Zydus Cadila Business Overview
  40. 8.7.3 Zydus Cadila Liposome Finished Pharmaceuticals Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Zydus Cadila Liposome Finished Pharmaceuticals Product Portfolio
  42. 8.7.5 Zydus Cadila Recent Developments
  43. 8.8 TTY Biopharma
  44. 8.8.1 TTY Biopharma Company Information
  45. 8.8.2 TTY Biopharma Business Overview
  46. 8.8.3 TTY Biopharma Liposome Finished Pharmaceuticals Revenue and Gross Margin (2021-2026)
  47. 8.8.4 TTY Biopharma Liposome Finished Pharmaceuticals Product Portfolio
  48. 8.8.5 TTY Biopharma Recent Developments
  49. 8.9 Sayre Therapeutics
  50. 8.9.1 Sayre Therapeutics Company Information
  51. 8.9.2 Sayre Therapeutics Business Overview
  52. 8.9.3 Sayre Therapeutics Liposome Finished Pharmaceuticals Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Sayre Therapeutics Liposome Finished Pharmaceuticals Product Portfolio
  54. 8.9.5 Sayre Therapeutics Recent Developments
  55. 8.10 Pacira
  56. 8.10.1 Pacira Company Information
  57. 8.10.2 Pacira Business Overview
  58. 8.10.3 Pacira Liposome Finished Pharmaceuticals Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Pacira Liposome Finished Pharmaceuticals Product Portfolio
  60. 8.10.5 Pacira Recent Developments
  61. 8.11 Luye Pharma
  62. 8.11.1 Luye Pharma Company Information
  63. 8.11.2 Luye Pharma Business Overview
  64. 8.11.3 Luye Pharma Liposome Finished Pharmaceuticals Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Luye Pharma Liposome Finished Pharmaceuticals Product Portfolio
  66. 8.11.5 Luye Pharma Recent Developments
  67. 8.12 Leadiant Biosciences
  68. 8.12.1 Leadiant Biosciences Company Information
  69. 8.12.2 Leadiant Biosciences Business Overview
  70. 8.12.3 Leadiant Biosciences Liposome Finished Pharmaceuticals Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Leadiant Biosciences Liposome Finished Pharmaceuticals Product Portfolio
  72. 8.12.5 Leadiant Biosciences Recent Developments
  73. 8.13 Kinyond
  74. 8.13.1 Kinyond Company Information
  75. 8.13.2 Kinyond Business Overview
  76. 8.13.3 Kinyond Liposome Finished Pharmaceuticals Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Kinyond Liposome Finished Pharmaceuticals Product Portfolio
  78. 8.13.5 Kinyond Recent Developments
  79. 8.14 Jazz
  80. 8.14.1 Jazz Company Information
  81. 8.14.2 Jazz Business Overview
  82. 8.14.3 Jazz Liposome Finished Pharmaceuticals Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Jazz Liposome Finished Pharmaceuticals Product Portfolio
  84. 8.14.5 Jazz Recent Developments
  85. 8.15 Ipsen
  86. 8.15.1 Ipsen Company Information
  87. 8.15.2 Ipsen Business Overview
  88. 8.15.3 Ipsen Liposome Finished Pharmaceuticals Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Ipsen Liposome Finished Pharmaceuticals Product Portfolio
  90. 8.15.5 Ipsen Recent Developments
  91. 8.16 Fudan-Zhangjiang
  92. 8.16.1 Fudan-Zhangjiang Company Information
  93. 8.16.2 Fudan-Zhangjiang Business Overview
  94. 8.16.3 Fudan-Zhangjiang Liposome Finished Pharmaceuticals Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Fudan-Zhangjiang Liposome Finished Pharmaceuticals Product Portfolio
  96. 8.16.5 Fudan-Zhangjiang Recent Developments
  97. 8.17 CSPC
  98. 8.17.1 CSPC Company Information
  99. 8.17.2 CSPC Business Overview
  100. 8.17.3 CSPC Liposome Finished Pharmaceuticals Revenue and Gross Margin (2021-2026)
  101. 8.17.4 CSPC Liposome Finished Pharmaceuticals Product Portfolio
  102. 8.17.5 CSPC Recent Developments
  103. 8.18 Bausch Health
  104. 8.18.1 Bausch Health Company Information
  105. 8.18.2 Bausch Health Business Overview
  106. 8.18.3 Bausch Health Liposome Finished Pharmaceuticals Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Bausch Health Liposome Finished Pharmaceuticals Product Portfolio
  108. 8.18.5 Bausch Health Recent Developments
  109. 8.19 Alnylam
  110. 8.19.1 Alnylam Company Information
  111. 8.19.2 Alnylam Business Overview
  112. 8.19.3 Alnylam Liposome Finished Pharmaceuticals Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Alnylam Liposome Finished Pharmaceuticals Product Portfolio
  114. 8.19.5 Alnylam Recent Developments
  115. 8.20 Acrotech Biopharma
  116. 8.20.1 Acrotech Biopharma Company Information
  117. 8.20.2 Acrotech Biopharma Business Overview
  118. 8.20.3 Acrotech Biopharma Liposome Finished Pharmaceuticals Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Acrotech Biopharma Liposome Finished Pharmaceuticals Product Portfolio
  120. 8.20.5 Acrotech Biopharma Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst